Honors & Awards

  • International Postdoc Grant in Medicine and Health, Vetenskapradet (2023-2025)

Professional Education

  • Master of Science, Universite Catholique De Louvain (2019)
  • Bachelor of Science, Universite Catholique De Louvain (2019)
  • Doctor of Philosophy, Uppsala Universitet (2023)
  • PhD, Uppsala University, Pharmaceutical Science (2023)
  • M. Sc., UCLouvain, Biomedical Science (2019)
  • Bs, UCLouvain, Biomedical Science (2019)

Stanford Advisors

All Publications

  • Non-invasive PET imaging of liver fibrogenesis using a RESCA-conjugated Affibody molecule. iScience Wegrzyniak, O., Lechi, F., Mitran, B., Cheung, P., Bitzios, A., Persson, J., Lofblom, J., Nordstrom, H., Eriksson, J., Frejd, F. Y., Korsgren, O., Zhang, B., Eriksson, O. 2024; 27 (5): 109688


    Non-invasive assessment of fibrogenic activity, rather than fibrotic scars, could significantly improve the management of fibrotic diseases and the development of anti-fibrotic drugs. This study explores the potential of an Affibody molecule (Z09591) labeled with the Al(18)F-restrained complexing agent (RESCA) method as a tracer for the non-invasive detection of fibrogenic cells. Z09591 was functionalized with the RESCA chelator for direct labeling with [18F]AlF. Invivo positron emission tomography/magnetic resonance imaging scans on U-87 tumor-bearing mice exhibited high selectivity of the resulting radiotracer, [18F]AlF-RESCA-Z09591, for platelet-derived growth factor receptor beta (PDGFRbeta), with minimal non-specific background uptake. Evaluation in a mouse model with carbon tetrachloride-induced fibrotic liver followed by a disease regression phase, revealed the radiotracer's high affinity and specificity for fibrogenic cells in fibrotic livers (standardized uptake value [SUV] 0.43± 0.05), with uptake decreasing during recovery (SUV 0.29± 0.03) (p<0.0001). [18F]AlF-RESCA-Z09591 accurately detects PDGFRbeta, offering non-invasive assessment of fibrogenic cells and promising applications in precise liver fibrogenesis diagnosis, potentially contributing significantly to anti-fibrotic drug development.

    View details for DOI 10.1016/j.isci.2024.109688

    View details for PubMedID 38660405

  • Noninvasive PET Detection of CD69-Positive Immune Cells Before Signs of Clinical Disease in Inflammatory Arthritis JOURNAL OF NUCLEAR MEDICINE Puuvuori, E., Shen, Y., Hulsart-Billstrom, G., Mitran, B., Zhang, B., Cheung, P., Wegrzyniak, O., Ingvast, S., Persson, J., Stahl, S., Korsgren, O., Lofblom, J., Wermeling, F., Eriksson, O. 2024; 65 (2): 294-299


    Rheumatoid arthritis (RA) is the most common inflammatory joint disease, and early diagnosis is key for effective disease management. CD69 is one of the earliest cell surface markers seen at the surface of activated immune cells, and CD69 is upregulated in synovial tissue in patients with active RA. In this study, we evaluated the performance of a CD69-targeting PET agent, [68Ga]Ga-DOTA-ZCAM241, for early disease detection in a model of inflammatory arthritis. Methods: A model of inflammatory arthritis was induced by transferring splenocytes from KRN T-cell receptor transgenic B6 mice into T-cell-deficient I-Ag7 major histocompatibility complex class II-expressing recipient mice. The mice were examined longitudinally by [68Ga]Ga-DOTA-ZCAM241 PET/CT before and 3, 7, and 12 d after induction of arthritis. Disease progression was monitored by clinical parameters, including measuring body weight and scoring the swelling of the paws. The uptake of [68Ga]Ga-DOTA-ZCAM241 in the paws was analyzed and expressed as SUVmean Tissue biopsy samples were analyzed for CD69 expression by flow cytometry or immunostaining for a histologic correlate. A second group of mice was examined by a nonbinding, size-matched Affibody molecule as the control. Results: Clinical symptoms appeared 5-7 d after induction of arthritis. The uptake of [68Ga]Ga-DOTA-ZCAM241 in the joints was negligible at baseline but increased gradually after disease induction. An elevated PET signal was found on day 3, before the appearance of clinical symptoms. The uptake of [68Ga]Ga-DOTA-ZCAM241 correlated with the clinical score and disease severity. The presence of CD69-positive cells in the joints and lymph nodes was confirmed by flow cytometry and immunostaining. The uptake of the nonbinding tracer that was the negative control also increased gradually with disease progression, although to a lesser extent than with [68Ga]Ga-DOTA-ZCAM241 Conclusion: The uptake of [68Ga]Ga-DOTA-ZCAM241 in the inflamed joints preceded the clinical symptoms in the KRN T-cell transfer model of inflammatory arthritis, in accordance with immunostaining for CD69. [68Ga]Ga-DOTA-ZCAM241 is thus a promising PET imaging marker of activated immune cells in tissue during RA onset.

    View details for DOI 10.2967/jnumed.123.266336

    View details for Web of Science ID 001206495700023

    View details for PubMedID 38050119

  • Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor NUCLEAR MEDICINE AND BIOLOGY Khalil, A., Hakhverdyan, S., Cheung, P., Bossart, M., Wagner, M., Eriksson, O., Velikyan, I. 2024; 128: 108876


    The beneficial role of glucose-dependent insulinotropic polypeptide receptor (GIPR) in weight control and maintaining glucose levels has led to the development of several multi-agonistic peptide drug candidates, targeting GIPR and glucagon like peptide 1 receptor (GLP1R) and/or the glucagon receptor (GCGR). The in vivo quantification of target occupancy by these drugs would accelerate the development of new drug candidates. The aim of this study was to evaluate a novel peptide (GIP1234), based on previously reported ligand DOTA-GIP-C803, modified with a fatty acid moiety to prolong its blood circulation. It would allow higher target tissue exposure and consequently improved peptide uptake as well as in vivo PET imaging and quantification of GIPR occupancy by novel drugs of interest.A 40 amino acid residue peptide (GIP1234) was synthesized based on DOTA-GIP-C803, in turn based on the sequences of endogenous GIP and Exendin-4 with specific amino acid modifications to obtain GIPR selectivity. A palmitoyl fatty acid chain was furthermore added at Lys14 via a glutamic acid linker to prolong its blood circulation time by the interaction with albumin. GIP1234 was conjugated with a DOTA chelator at the C-terminal cysteine residue to achieve 68Ga radiolabeling. The resulting PET probe, [68Ga]Ga-DOTA-GIP1234 was evaluated for receptor binding specificity and selectivity using HEK293 cells transfected with human GIPR, GLP1R, or GCGR. Blocking experiments with tirzepatide (2 μM) were conducted using huGIPR HEK293 cells to investigate binding specificity. Ex vivo and in vivo organ distribution of [68Ga]Ga-DOTA-GIP1234 was studied in rats and a pig in comparison to [68Ga]Ga-DOTA-C803-GIP. Binding of [68Ga]Ga-DOTA-GIP1234 to albumin was assessed in situ using polyacrylamide gel electrophoresis (PAGE). The stability was tested in formulation buffer and rat blood plasma.[68Ga]Ga-DOTA-GIP1234 was synthesized with non-decay corrected radiochemical yield of 88 ± 3.7 % and radiochemical purity of 97.8 ± 0.8 %. The molar activity for the radiotracer was 8.1 ± 1.1 MBq/nmol. [68Ga]Ga-DOTA-GIP1234 was stable and maintained affinity to huGIPR HEK293 cells (dissociation constant (Kd) = 40 ± 12.5 nM). The binding of [68Ga]Ga-DOTA-GIP1234 to huGCGR and huGLP1R cells was insignificant. Pre-incubation of huGIPR HEK293 cell sections with tirzepatide resulted in the decrease of [68Ga]Ga-DOTA-GIP1234 binding by close to 90 %. [68Ga]Ga-DOTA-GIP1234 displayed slow blood clearance in pigs with SUV = 3.5 after 60 min. Blood retention of the tracer in rat was 2-fold higher than that of [68Ga]Ga-DOTA-C803-GIP. [68Ga]Ga-DOTA-GIP1234 also demonstrated strong liver uptake in both pig and rat combined with decreased renal excretion. The concentration dependent binding of [68Ga]Ga-DOTA-GIP1234 to albumin was confirmed in situ by PAGE.[68Ga]Ga-DOTA-GIP1234 demonstrated nanomolar affinity and selectivity for huGIPR in vitro. Addition of a fatty acid moiety prolonged blood circulation time and tissue exposure in both rat and pig in vivo. However, the liver uptake was also increased which may make PET imaging of abdominal tissues such as pancreas challenging. The investigation of the influence of fatty acid moiety on the biological performance of the peptide ligand paved the way for further rational design of GIPR ligand analogues with improved characteristics.

    View details for DOI 10.1016/j.nucmedbio.2024.108876

    View details for Web of Science ID 001171488500001

    View details for PubMedID 38241936

  • Preclinical evaluation of Affibody molecule for PET imaging of human pancreatic islets derived from stem cells EJNMMI RESEARCH Cheung, P., Thorngren, J., Zhang, B., Vasylovska, S., Lechi, F., Persson, J., Stahl, S., Lofblom, J., Korsgren, O., Eriksson, J., Lau, J., Eriksson, O. 2023; 13 (1): 107


    Beta-cell replacement methods such as transplantation of isolated donor islets have been proposed as a curative treatment of type 1 diabetes, but widespread application is challenging due to shortages of donor tissue and the need for continuous immunosuppressive treatments. Stem-cell-derived islets have been suggested as an alternative source of beta cells, but face transplantation protocols optimization difficulties, mainly due to a lack of available methods and markers to directly monitor grafts survival, as well as their localization and function. Molecular imaging techniques and particularly positron emission tomography has been suggested as a tool for monitoring the fate of islets after clinical transplantation. The integral membrane protein DGCR2 has been demonstrated to be a potential pancreatic islet biomarker, with specific expression on insulin-positive human embryonic stem-cell-derived pancreatic progenitor cells. The candidate Affibody molecule ZDGCR2:AM106 was radiolabeled with fluorine-18 using a novel click chemistry-based approach. The resulting positron emission tomography tracer [18F]ZDGCR2:AM106 was evaluated for binding to recombinant human DGCR2 and cryosections of stem-cell-derived islets, as well as in vivo using an immune-deficient mouse model transplanted with stem-cell-derived islets. Biodistribution of the [18F]ZDGCR2:AM106 was also assessed in healthy rats and pigs.[18F]ZDGCR2:AM106 was successfully synthesized with high radiochemical purity and yield via a pretargeting approach. [18F]ZDGCR2:AM106 retained binding to recombinant human DCGR2 as well as to cryosectioned stem-cell-derived islets, but in vivo binding to native pancreatic tissue in both rat and pig was low. However, in vivo uptake of [18F]ZDGCR2:AM106 in stem-cell-derived islets transplanted in the immunodeficient mice was observed, albeit only within the early imaging frames after injection of the radiotracer.Targeting of DGCR2 is a promising approach for in vivo detection of stem-cell-derived islets grafts by molecular imaging. The synthesis of [18F]ZDGCR2:AM106 was successfully performed via a pretargeting method to label a site-specific covalently bonded fluorine-18 to the Affibody molecule. However, the rapid washout of [18F]ZDGCR2:AM106 from the stem-cell-derived islets graft indicates that dissociation kinetics can be improved. Further studies using alternative binders of similar classes with improved binding potential are warranted.

    View details for DOI 10.1186/s13550-023-01057-3

    View details for Web of Science ID 001125115500001

    View details for PubMedID 38100042

    View details for PubMedCentralID PMC10724103

  • [<SUP>18</SUP>F]MK-7246 for Positron Emission Tomography imaging of beta cells surface marker GRP44 Cheung, P., Amin, M., Zhang, B., Lechi, F., Korsgren, O., Eriksson, J., Odell, L. R., Eriksson, O. ELSEVIER SCIENCE INC. 2023: S199-S200
  • Non-invasive assessment of fibrogenesis by PET imaging using a [Al<SUP>18</SUP>F]RESCA-Affibody molecule targeting PDGFRβ Wegrzyniak, O., Lechi, F., Zhang, B., Mitran, B., Cheung, P., Bitzios, A., Hulsart-Billstrom, G., Persson, J., Lofblom, J., Nordstrom, H., Eriksson, J., Frejd, F., Korsgren, O., Eriksson, O. ELSEVIER SCIENCE INC. 2023: S204-S205
  • [68Ga]Ga-DOTA-GIP1234 for PET imaging of glucose-dependent insulinotropic polypeptide receptor (GIPR) Khalil, A., Velikyan, I., Hakhverdyan, S., Cheung, P., Bossart, M., Wagner, M., Eriksson, O. ELSEVIER SCIENCE INC. 2023: S201
  • Imaging of fibrogenesis in the liver by [<SUP>18</SUP>F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β EJNMMI RADIOPHARMACY AND CHEMISTRY Wegrzyniak, O., Zhang, B., Rokka, J., Rosestedt, M., Mitran, B., Cheung, P., Puuvuori, E., Ingvast, S., Persson, J., Nordstroem, H., Loefblom, J., Ponten, F., Frejd, F. Y., Korsgren, O., Eriksson, J., Eriksson, O. 2023; 8 (1): 23


    Platelet-derived growth factor receptor beta (PDGFRβ) is a receptor overexpressed on activated hepatic stellate cells (aHSCs). Positron emission tomography (PET) imaging of PDGFRβ could potentially allow the quantification of fibrogenesis in fibrotic livers. This study aims to evaluate a fluorine-18 radiolabeled Affibody molecule ([18F]TZ-Z09591) as a PET tracer for imaging liver fibrogenesis.In vitro specificity studies demonstrated that the trans-Cyclooctenes (TCO) conjugated Z09591 Affibody molecule had a picomolar affinity for human PDGFRβ. Biodistribution performed on healthy rats showed rapid clearance of [18F]TZ-Z09591 through the kidneys and low liver background uptake. Autoradiography (ARG) studies on fibrotic livers from mice or humans correlated with histopathology results. Ex vivo biodistribution and ARG revealed that [18F]TZ-Z09591 binding in the liver was increased in fibrotic livers (p = 0.02) and corresponded to binding in fibrotic scars.Our study highlights [18F]TZ-Z09591 as a specific tracer for fibrogenic cells in the fibrotic liver, thus offering the potential to assess fibrogenesis clearly.

    View details for DOI 10.1186/s41181-023-00210-6

    View details for Web of Science ID 001075551000001

    View details for PubMedID 37733133

    View details for PubMedCentralID PMC10513984

  • PET Imaging of Neutrophil Elastase with 11C-GW457427 in Acute Respiratory Distress Syndrome in Pigs JOURNAL OF NUCLEAR MEDICINE Puuvuori, E., Chiodaroli, E., Estrada, S., Cheung, P., Lubenow, N., Sigfridsson, J., Romelin, H., Ingvast, S., Elgland, M., Liggieri, F., Korsgren, O., Perchiazzi, G., Eriksson, O., Antoni, G. 2023; 64 (3): 423-429


    Today, there is a lack of clinically available imaging techniques to detect and quantify specific immune cell populations. Neutrophils are one of the first immune cells at the site of inflammation, and they secrete the serine protease neutrophil elastase (NE), which is crucial in the fight against pathogens. However, the prolonged lifespan of neutrophils increases the risk that patients will develop severe complications, such as acute respiratory distress syndrome (ARDS). Here, we evaluated the novel radiolabeled NE inhibitor 11C-GW457427 in a pig model of ARDS, for detection and quantification of neutrophil activity in the lungs. Methods: ARDS was induced by intravenous administration of oleic acid to 5 farm pigs, and 4 were considered healthy controls. The severity of ARDS was monitored by clinical parameters of lung function and plasma biomarkers. Each pig was studied with 11C-GW457427 and PET/CT, before and after pretreatment with the NE inhibitor GW311616 to determine in vivo binding specificity. PET image data were analyzed as SUVs and correlated with immunohistochemical staining for NE in biopsies. Results: The binding of 11C-GW457427 was increased in pig lungs with induced ARDS (median SUVmean, 1.91; interquartile range [IQR], 1.67-2.55) compared with healthy control pigs (P < 0.05 and P = 0.03, respectively; median SUVmean, 1.04; IQR, 0.66-1.47). The binding was especially strong in lung regions with high levels of NE and ongoing inflammation, as verified by immunohistochemistry. The binding was successfully blocked by pretreatment of an NE inhibitor drug, which demonstrated the in vivo specificity of 11C-GW457427 (P < 0.05 and P = 0.04, respectively; median SUVmean, 0.60; IQR, 0.58-0.77). The binding in neutrophil-rich tissues such as bone marrow (P < 0.05 and P = 0.04, respectively; baseline median SUVmean, 5.01; IQR, 4.48-5.49; block median SUVmean, 1.57; IQR, 0.95-1.85) and spleen (median SUVmean, 2.14; IQR, 1.19-2.36) was also high in all pigs. Conclusion: 11C-GW457427 binds to NE in a porcine model of oleic acid-induced lung inflammation in vivo, with a specific increase in regional lung, bone marrow, and spleen SUV. 11C-GW457427 is a promising tool for localizing, tracking, and quantifying neutrophil-facilitated inflammation in clinical diagnostics and drug development.

    View details for DOI 10.2967/jnumed.122.264306

    View details for Web of Science ID 000975392000016

    View details for PubMedID 36109184

    View details for PubMedCentralID PMC10071803

  • [<SUP>18</SUP>F]MK-7246 for Positron Emission Tomography Imaging of the Beta-Cell Surface Marker GPR44 PHARMACEUTICS Cheung, P., Amin, M. A., Zhang, B., Lechi, F., Korsgren, O., Eriksson, J., Odell, L. R., Eriksson, O. 2023; 15 (2)


    The progressive loss of beta-cell mass is a hallmark of diabetes and has been suggested as a complementary approach to studying the progression of diabetes in contrast to the beta-cell function. Non-invasive nuclear medicinal imaging techniques such as Positron Emission Tomography using radiation emitting tracers have thus been suggested as more viable methodologies to visualize and quantify the beta-cell mass with sufficient sensitivity. The transmembrane G protein-coupled receptor GPR44 has been identified as a biomarker for monitoring beta-cell mass. MK-7246 is a GPR44 antagonist that selectively binds to GPR44 with high affinity and good pharmacokinetic properties. Here, we present the synthesis of MK-7246, radiolabeled with the positron emitter fluorine-18 for preclinical evaluation using cell lines, mice, rats and human pancreatic cells. Here, we have described a synthesis and radiolabeling method for producing [18F]MK-7246 and its precursor compound. Preclinical assessments demonstrated the strong affinity and selectivity of [18F]MK-7246 towards GPR44. Additionally, [18F]MK-7246 exhibited excellent metabolic stability, a fast clearance profile from blood and tissues, qualifying it as a promising radioactive probe for GPR44-directed PET imaging.

    View details for DOI 10.3390/pharmaceutics15020499

    View details for Web of Science ID 000940959200001

    View details for PubMedID 36839820

    View details for PubMedCentralID PMC9962486

  • Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB Wegrzyniak, O., Rokka, J., Zhang, B., Rosestedt, M., Mitran, B., Cheung, P., Puuvuori, E., Ingvast, S., Ponten, F., Frejd, F., Korsgren, O., Eriksson, J., Eriksson, O. ELSEVIER. 2022: S471
  • PET imaging of lung inflammation in pig by neutrophil elastase inhibitor [<SUP>11</SUP>C]GW457427 Eriksson, O., Puuvuori, E., Chiodaroli, E., Liggieri, F., Sigfridsson, J., Romelin, H., Ingvast, S., Estrada, S., Elgland, M., Cheung, P., Korsgren, O., Perchiazzi, G., Antoni, G. ELSEVIER SCIENCE INC. 2022: S65
  • Evaluation of Affibody molecule Z09591 for PET imaging in fibrosis Wegrzyniak, O., Rokka, J., Zhang, B., Rosestedt, M., Cheung, P., Mitran, B., Ingvast, S., Puuvuori, E., Ponten, F., Frejd, F., Korsgren, O., Eriksson, J., Eriksson, O. ELSEVIER SCIENCE INC. 2022: S44
  • Synthesis of [<SUP>18</SUP>F]MK7246 for beta cell mass imaging Zhang, B., Cheung, P., Amin, M., Odell, L. R., Korsgren, O., Eriksson, O., Eriksson, J. ELSEVIER SCIENCE INC. 2022: S40-S41
  • The Current State of Beta-Cell-Mass PET Imaging for Diabetes Research and Therapies BIOMEDICINES Cheung, P., Eriksson, O. 2021; 9 (12)


    Diabetes is a chronic metabolic disease affecting over 400 million people worldwide and one of the leading causes of death, especially in developing nations. The disease is characterized by chronic hyperglycemia, caused by defects in the insulin secretion or action pathway. Current diagnostic methods measure metabolic byproducts of the disease such as glucose level, glycated hemoglobin (HbA1c), insulin or C-peptide levels, which are indicators of the beta-cell function. However, they inaccurately reflect the disease progression and provide poor longitudinal information. Beta-cell mass has been suggested as an alternative approach to study disease progression in correlation to beta-cell function, as it behaves differently in the diabetes physiopathology. Study of the beta-cell mass, however, requires highly invasive and potentially harmful procedures such as pancreatic biopsies, making diagnosis and monitoring of the disease tedious. Nuclear medical imaging techniques using radiation emitting tracers have been suggested as strong non-invasive tools for beta-cell mass. A highly sensitive and high-resolution technique, such as positron emission tomography, provides an ideal solution for the visualization of beta-cell mass, which is particularly essential for better characterization of a disease such as diabetes, and for estimating treatment effects towards regeneration of the beta-cell mass. Development of novel, validated biomarkers that are aimed at beta-cell mass imaging are thus highly necessary and would contribute to invaluable breakthroughs in the field of diabetes research and therapies. This review aims to describe the various biomarkers and radioactive probes currently available for positron emission tomography imaging of beta-cell mass, as well as highlight the need for precise quantification and visualization of the beta-cell mass for designing new therapy strategies and monitoring changes in the beta-cell mass during the progression of diabetes.

    View details for DOI 10.3390/biomedicines9121824

    View details for Web of Science ID 000736153800001

    View details for PubMedID 34944640

    View details for PubMedCentralID PMC8698817

  • The <i>Drosophila melanogaster</i> Levodopa-Induced Depression Model Exhibits Negative Geotaxis Deficits and Differential Gene Expression in Males and Females FRONTIERS IN NEUROSCIENCE Moulin, T. C., Ferro, F., Hoyer, A., Cheung, P., Williams, M. J., Schioth, H. B. 2021; 15: 653470


    More than 320 million people live with depression in the world, a disorder that severely limits psychosocial functioning and diminishes quality of life. The prevalence of major depression is almost two times higher in women than in men. However, the molecular mechanisms of its sex-specific pathophysiology are still poorly understood. Drosophila melanogaster is an established model for neurobiological research of depression-like states, as well as for the study of molecular and genetic sex differences in the brain. Here, we investigated sex-specific effects on forced-climbing locomotion (negative geotaxis) and gene expression of a fly model of depression-like phenotypes induced by levodopa administration, which was previously shown to impair normal food intake, mating frequency, and serotonin concentration. We observed that both males and females show deficits in the forced-climbing paradigm; however, modulated by distinct gene expression patterns after levodopa administration. Our results suggest that Drosophila models can be a valuable tool for identifying the molecular mechanisms underlying the difference of depressive disorder prevalence between men and women.

    View details for DOI 10.3389/fnins.2021.653470

    View details for Web of Science ID 000656126900001

    View details for PubMedID 34079435

    View details for PubMedCentralID PMC8165388

  • PET Imaging of GPR44 by Antagonist [<SUP>11</SUP>C]MK-7246 in Pigs BIOMEDICINES Cheung, P., Zhang, B., Puuvuori, E., Estrada, S., Amin, M. A., Ye, S., Korsgren, O., Odell, L. R., Eriksson, J., Eriksson, O. 2021; 9 (4)


    A validated imaging marker for beta-cell mass would improve understanding of diabetes etiology and enable new strategies in therapy development. We previously identified the membrane-spanning protein GPR44 as highly expressed and specific to the beta cells of the pancreas. The selective GPR44 antagonist MK-7246 was radiolabeled with carbon-11 and the resulting positron-emission tomography (PET) tracer [11C]MK-7246 was evaluated in a pig model and in vitro cell lines. The [11C]MK-7246 compound demonstrated mainly hepatobiliary excretion with a clearly defined pancreas, no spillover from adjacent tissues, and pancreatic binding similar in magnitude to the previously evaluated GPR44 radioligand [11C]AZ12204657. The binding could be blocked by preadministration of nonradioactive MK-7246, indicating a receptor-binding mechanism. [11C]MK-7246 showed strong potential as a PET ligand candidate for visualization of beta-cell mass (BCM) and clinical translation of this methodology is ongoing.

    View details for DOI 10.3390/biomedicines9040434

    View details for Web of Science ID 000642807100001

    View details for PubMedID 33923731

    View details for PubMedCentralID PMC8073488

  • Longitudinal Assessment of <SUP>11</SUP>C-5-Hydroxytryptophan Uptake in Pancreas After Debut of Type 1 Diabetes DIABETES Espes, D., Carlsson, P., Selvaraju, R., Rosestedt, M., Cheung, P., Ahlstrom, H., Korsgren, O., Eriksson, O. 2021; 70 (4): 966-975


    The longitudinal alterations of the pancreatic β-cell and islet mass in the progression of type 1 diabetes (T1D) are still poorly understood. The objective of this study was to repeatedly assess the endocrine volume and the morphology of the pancreas for up to 24 months after T1D diagnosis (n = 16), by 11C-5-hydroxytryptophan (11C-5-HTP) positron emission tomography (PET) and MRI. Study participants were examined four times by PET/MRI: at recruitment and then after 6, 12, and 24 months. Clinical examinations and assessment of β-cell function by a mixed-meal tolerance test and fasting blood samples were performed in connection with the imaging examination. Pancreas volume has a tendency to decrease from 50.2 ± 10.3 mL at T1D debut to 42.2 ± 14.6 mL after 24 months (P < 0.098). Pancreas uptake of 11C-5-HTP (e.g., the volume of the endocrine pancreas) did not decrease from T1D diagnosis (0.23 ± 0.10 % of injected dose) to 24-month follow-up, 0.21 ± 0.14% of injected dose, and exhibited low interindividual changes. Pancreas perfusion was unchanged from diagnosis to 24-month follow-up. The pancreas uptake of 11C-5-HTP correlated with the long-term metabolic control as estimated by HbA1c (P < 0.05). Our findings argue against a major destruction of β-cell or islet mass in the 2-year period after diagnosis of T1D.

    View details for DOI 10.2337/db20-0776

    View details for Web of Science ID 000630537100013

    View details for PubMedID 33479059